According to the Customs Tariff Commission of the State Council, China will begin reducing its import tariffs on several medical goods starting in 2026. The purpose of this policy is to allow for increased access to sophisticated medical technology like artificial blood... Read More
The National Reimbursement Drug List (NRDL) for 2025 has been announced by the Chinese government and includes 114 new entries, 50 of which are first-in-world innovative therapies. These additions show an increased focus from the government on making high-value medicines available to... Read More
India’s Central Drugs Standard Control Organization (CDSCO) has released the final list of risk classifications for oncology-related medical devices. The classification system, published on January 2, 2026, improves transparency concerning the regulation of cancer med-tech devices. It gives manufacturers of oncology devices... Read More
Approximately 50% of global clinical trials are conducted in the Asia Pacific region today. The clinical trial landscape of Asia has been expanding beyond China in recent years. Although over 60% of the clinical trials in the region were initiated in China... Read More
On January 27, 2026, China’s State Council issued revised Implementing Regulations of the Drug Administration Law of the People’s Republic of China, which will go into effect on May 15, 2026. The regulations refine key provisions of the Drug Administration Law, which... Read More
In late 2025, China’s regulatory landscape for pharmaceuticals changed rapidly due to a number of policies that indicate the government’s commitment to increasing innovation while ensuring adequate oversight and compliance. Recent reforms issued by the NMPA, the State Council, and the National... Read More
China continues to reshape its drug market access system in an effort to balance affordability with better healthcare for its citizens. At the core of this transformation are two reimbursement pathways: National Reimbursement Drug List (NRDL) and Volume-Based Procurement (VBP). Recent policy... Read More
Due to the rising prevalence of chronic conditions such as cancer and diabetes in China and the increased focus on early diagnosis and reduced treatment costs, the in vitro diagnostics (IVD) market in China is growing rapidly. The National Medical Products Administration... Read More
Recent reforms to medical device registration in China are revamping how innovative products are approved for market entry. Collectively, these measures aim to reduce regulatory hurdles, enhance quality systems, encourage digital transformation, and promote international collaboration. This signals China’s ambition to move... Read More
While in the past, the US, EU, and Japan dominated the global medical device market, things are changing as more new devices are being developed in Asia first, especially in China. Accordingly, Korea and China have recently announced new initiatives aimed at... Read More